pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Carvykti · news · pharmadog
← back to Carvykti
News mentioning Carvykti
25
stories
3d
Pfizer leaps into ‘in vivo’ CAR-T with latest China deal
biopharma dive
11d
China has a clear shot to 2030 goals, though economic, cultural barriers remain
biospace
15d
Forge’s Piteri-Molina on AI, Ohio and what’s next for gene therapy manufacturing
biospace
18d
6 potential blockbusters that could pave China’s path to 2030 ambitions
biospace
Oct 20, 26
Most new drugs are still too costly at launch, ICER says
biopharma dive
Sep 25, 26
Legend's five-year data suggests Carvykti could be a cure; Addex, Indivior split
endpoints
Sep 25, 26
J&J, Legend tout long-term survival benefits for Carvykti in multiple myeloma
biospace
Sep 18, 26
Legend names new CEO as Carvykti competition grows; Vertex makes a flurry of moves
endpoints
Sep 17, 26
Chutes & Ladders—Legend poaches Novartis vet to boost commercial potential
fiercebiotech
Sep 14, 26
Unlocking cell surface protein research with site-specific labeling
biospace
Sep 3, 26
The hidden scale-out problem behind CAR-T’s growth
biopharma dive
Aug 13, 26
Chutes & Ladders—Former Legend CEO lands at K2
fiercebiotech
Aug 11, 26
Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs
biopharma dive
Aug 5, 26
4 potential biotech M&A targets, plus a pretty sure bet from J&J
biospace
Jul 30, 26
Chutes & Ladders—Legend CEO departs without successor in place
fiercebiotech
Jul 30, 26
J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
biopharma dive
Jul 30, 26
J&J secures right to take the helm in up to $925M Sail CAR T pact
biospace
Jul 27, 26
FDA scientists question Capricor data; Legend CEO steps down
biopharma dive
Jul 27, 26
Legend CEO Ying Huang resigns; Carvykti chief named interim leader
endpoints
Jul 27, 26
Legend Biotech CEO abruptly steps down without permanent replacement
fiercebiotech
Jul 27, 26
Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
biospace
Jul 22, 26
Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely on
biospace
Jul 15, 26
J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
biopharma dive
Jun 3, 26
Legend surges on early data for ‘in vivo’ lymphoma cell therapy
biopharma dive
Jun 2, 26
Legend Biotech shares first in vivo CAR-T data, its next act after Carvykti
endpoints